ISI Web of Knowledge Take the next step  
Web of Science®
 
Previous Record (inactive) Record 1  of  1 Next Record (inactive)
Record from Web of Science®
THERAPY OF EXPERIMENTAL HUMAN BRAIN-TUMORS USING A NEUROATTENUATED HERPES-SIMPLEX VIRUS MUTANT
Author(s): KESARI S, RANDAZZO BP, VALYINAGY T, HUANG QS, BROWN SM, MACLEAN AR, LEE VMY, TROJANOWSKI JQ, FRASER NW
Source: LABORATORY INVESTIGATION    Volume: 73    Issue: 5    Pages: 636-648    Published: NOV 1995  
Times Cited: 95     References: 55     
Abstract: BACKGROUND: Engineered herpes simplex virus (HSV) strains previously have been shown to offer a potential therapeutic alternative to conventional treatment modalities for brain tumors. Because HSV Type 1 strain 1716 has a deletion in the gamma 34.5 neurovirulence gene that renders it avirulent in the mouse central nervous system, we have assessed its potential to induce selective lysis of tumor cells versus neurons in vitro and in vivo.

EXPERIMENTAL DESIGN: To do this, we studied parental HSV-1 strain 17(+) and strain 1716 using human embryonal carcinoma cells (NT2 cells). These cells resemble neuronal progenitor cells and can be induced to differentiate into neurons (NT2N) with retinoic acid. Intracerebral grafts of NT2 cells into the brains of nude mice resulted in lethal brain tumors, and grafts of NT2N cells resulted in the integration of NT2N cells.

RESULTS: In vitro studies showed that strain 1716 replicates in and spreads on monolayers of NT2 cells but not in NT2N cells. In vivo, strain 1716 replicated preferentially in NT2 tumors as evidenced by immunohistochemical staining for viral antigens, by in situ hybridization for HSV-specific transcripts, and by titration of virus from brains with tumor after intracranial injection of the virus into these mice. The temporal regression of NT2 tumors in mice treated with strain 1716 was demonstrated in vivo by magnetic resonance imaging. Electron microscopy and studies of DNA fragmentation suggested that regression of NT2 brain tumors in strain 1716-treated mice was mainly caused by a nonapoptotic, lytic mode of cell death. Finally, strain 1716-treated NT2 tumor-bearing mice survived more than twice as long as mock-treated tumor-bearing mice, and these differences in survival (25 vs. 9 weeks) were statistically significant (p < 0.03).

CONCLUSIONS: We conclude from these studies that strain 1716 induces regression of human neural tumors established in the brains of nude mice, resulting in their prolonged survival.

Document Type: Article
Language: English
Addresses:
1. WISTAR INST ANAT & BIOL, PHILADELPHIA, PA 19104 USA
2. UNIV PENN, SCH MED, DEPT PATHOL & LAB MED, DIV ANAT PATHOL, PHILADELPHIA, PA 19104 USA
3. MRC, INST VIROL, GLASGOW, LANARK SCOTLAND
Publisher: WILLIAMS & WILKINS, 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436
Subject Category: Medicine, Research & Experimental; Pathology
IDS Number: TH832
ISSN: 0023-6837
Previous Record (inactive) Record 1  of  1 Next Record (inactive)
Record from Web of Science®
  
Thomson Reuters Logo